By Billy Candra 
This pivotal study represents a significant leap forward in understanding the complex interplay of factors that predispose childhood cancer survivors to subsequent malignancies. For decades, the medical community has recognized the long-term adverse effects of aggressive cancer treatments administered during childhood, including chemotherapy and radiation. However, the precise proportional contribution of these treatments versus an individual’s inherent genetic predisposition and lifestyle choices has remained largely unquantified at a population level. This research not only confirms the previously acknowledged associations but also provides a crucial quantitative framework for assessing risk, paving the way for more personalized and effective survivorship care strategies.
Unpacking the Burden of Secondary Cancers
"We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated corresponding author Yadav Sapkota, PhD, from St. Jude’s Department of Epidemiology and Cancer Control. Dr. Sapkota emphasized the novelty of the findings, noting, "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification is vital for clinicians and researchers seeking to refine risk assessment models and tailor intervention strategies.
Childhood cancer, though relatively rare, has seen remarkable improvements in survival rates over the past half-century. Innovations in chemotherapy, radiation therapy, and surgical techniques have transformed many once-fatal diagnoses into treatable conditions. Today, more than 85% of children diagnosed with cancer will survive five years or more. While this represents a monumental medical triumph, it has also created a growing population of adult survivors who face unique health challenges, including a heightened risk for chronic health conditions and, most critically, secondary cancers. These subsequent malignancies are not recurrences of the original cancer but entirely new cancers that develop years or even decades after initial treatment.
Methodology and Unprecedented Data Scale
Previous research has typically examined the association between specific treatment exposures, genetic factors, or lifestyle choices and an increased risk of second cancers in isolation. Such studies, while valuable, could not provide a comprehensive picture of the relative contributions of these diverse factors within a survivor population. To address this critical knowledge gap, St. Jude scientists undertook an ambitious comparative analysis involving over 10,000 survivors drawn from the St. Jude LIFE and CCSS cohorts. Combined, these cohorts represent the largest collection of childhood cancer survivors in North America, offering an unparalleled dataset for robust statistical analysis.
This expansive dataset meticulously cataloged a wealth of information, including detailed records of original cancer diagnoses and treatment exposures (such as specific chemotherapy agents and radiation fields/doses), comprehensive genetic information (including both common and rare variants), lifestyle factors (such as diet and exercise habits), and, crucially, the presence or absence of a second cancer. This holistic approach allowed researchers to disentangle and evaluate the independent and collective contributions of these myriad factors to the incidence of secondary malignancies.
Co-author Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control, underscored the unique capabilities afforded by these cohorts: "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." The sheer volume and depth of genetic and clinical data were instrumental in enabling the sophisticated statistical modeling required to apportion risk contributions with such precision.
Key Findings: Radiation, Genetics, and Chemotherapy Contributions
The study’s findings illuminated the distinct roles played by various risk factors. Radiation exposure emerged as the most significant individual contributor to secondary cancer risk, accounting for approximately 40% or more of the overall risk. This finding aligns with and further solidifies prior research that has extensively documented the long-term adverse effects of radiation therapy. Recognizing these risks, modern pediatric oncology practices have already undergone significant shifts, with contemporary therapies employing lower radiation doses, more targeted delivery techniques, or entirely eliminating radiation exposure in favor of other effective treatments whenever possible. This study provides compelling, data-driven support for these ongoing efforts to minimize radiation burden in pediatric cancer patients.
While the impact of radiation exposure was relatively straightforward, the researchers uncovered more complex and nuanced relationships for chemotherapy and genetic predisposition. Chemotherapy contributed between 8% and 35% of subsequent cancer risk, depending on the specific type of secondary cancer. The potential late effects of various chemotherapy agents, including their genotoxic and mutagenic properties, have been well-described in the literature. However, the quantitative contribution of genetic predisposition to second cancer risk in survivors has been less thoroughly understood and appreciated until now.
To delve deeper into this genetic component, the research team investigated hundreds of common genetic variants previously linked to cancer development in the general population, which were aggregated into a "polygenic risk score." They also examined certain rare genetic variants. By analyzing the relationship between these genetic markers and the incidence of second cancers in St. Jude LIFE and CCSS participants, they made a striking discovery: the polygenic risk score contributed between 5% and 37% of the risk, depending on the specific cancer type.
The Unforeseen Power of Genetics and Polygenic Risk Scores
The revelation regarding the significant role of genetics challenges conventional wisdom in the field. "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population," explained co-author Yutaka Yasui, PhD, from St. Jude’s Department of Epidemiology and Cancer Control. "Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures."
Dr. Sapkota further highlighted the paradigm-shifting nature of these genetic findings: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This statement underscores a critical recalibration in how clinicians and researchers should conceptualize and assess risk in this vulnerable population. It suggests that while treatment history remains paramount, an individual’s inherent genetic blueprint can be a powerful, and sometimes dominant, determinant of future cancer risk.
In contrast to the substantial contributions of treatment and genetics, lifestyle factors, such as diet and exercise, appeared to contribute much less to second cancer risk in this particular study, accounting for only 1% to 6%. However, the researchers offered an important caveat: the survivors included in this study were primarily in their 20s and 30s. It is plausible that lifestyle factors, which often exert their effects cumulatively over longer periods, may not yet have had sufficient time to manifest their full impact on secondary cancer development within this relatively young cohort.
"We know healthy lifestyle choices are important for survivors," Sapkota affirmed. "In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This distinction is crucial; while lifestyle’s direct impact on secondary cancer risk might be limited at younger ages, its broader benefits for overall health and other late effects of treatment remain undeniable and warrant continued emphasis in survivorship care.
Reshaping Survivorship Care Guidelines
The implications of these findings for the future of childhood cancer survivorship care are profound. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Sapkota noted. "Our study suggests that we need to better account for genetic predisposition in this population." This paradigm shift necessitates a re-evaluation of current survivorship care guidelines, potentially integrating genetic risk assessment more formally into routine clinical practice.
For survivors identified with a strong genetic predisposition to specific secondary cancers, the findings suggest a compelling rationale for more regular and intensive cancer screenings. Early detection remains a cornerstone of successful cancer treatment, and tailored surveillance protocols based on individual genetic and treatment-related risks could significantly improve outcomes. Armed with the knowledge of their unique combination of treatment-related, genetic, and lifestyle risk factors, survivors could also become more empowered advocates, engaging more proactively with their healthcare providers to discuss the need for such personalized screening and preventative strategies.
This study could catalyze several significant changes within the medical community. Oncologists, primary care physicians, and genetic counselors may need enhanced training to interpret polygenic risk scores and effectively communicate these complex risk profiles to survivors. Furthermore, patient advocacy groups could leverage these findings to push for greater access to genetic testing and counseling services for childhood cancer survivors, ensuring that this crucial information becomes an integral part of their long-term health management.
Broader Impact and Future Directions
The ultimate goal of this research is to extend and improve the lives of childhood cancer survivors. "Second cancers remain the leading cause of mortality for childhood cancer survivors," Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives."
This understanding paves the way for a more targeted approach to prevention. For instance, pharmaceutical research could focus on developing interventions that mitigate the effects of specific genetic predispositions or counteract the long-term sequelae of certain chemotherapies. Public health initiatives could be designed to educate survivors and healthcare providers about the importance of genetic screening and personalized surveillance.
Future research will likely build upon these foundations, seeking to refine polygenic risk scores for even greater predictive accuracy and to explore the interplay between genetics, treatment, and environmental factors in more granular detail. As the cohort ages, it will also be crucial to re-evaluate the long-term impact of lifestyle factors, which may become more prominent as survivors reach older adulthood. The integration of artificial intelligence and machine learning could further enhance the ability to predict individual risk profiles, moving closer to a truly personalized medicine approach for this vulnerable population.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude Children’s Research Hospital. The study’s other authors include Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison, and Yutaka Yasui, all from St. Jude. Additional contributors include Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte, and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
The invaluable research was supported by substantial grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547, and CA21765) and ALSAC, the dedicated fundraising and awareness organization of St. Jude Children’s Research Hospital. This comprehensive funding underscores the critical importance and collaborative nature of this extensive research effort, promising to transform long-term care for childhood cancer survivors globally.
